Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Sales (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Return on Sales readings, the most recent being 0.01% for Q4 2025.

  • On a quarterly basis, Return on Sales rose 1.0% to 0.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.01%, a 1.0% increase, with the full-year FY2025 number at 0.01%, changed 0.0% from a year prior.
  • Return on Sales hit 0.01% in Q4 2025 for Enanta Pharmaceuticals, up from 0.01% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.01% in Q4 2025 to a low of 0.03% in Q3 2021.
  • Median Return on Sales over the past 5 years was 0.01% (2023), compared with a mean of 0.02%.
  • Biggest five-year swings in Return on Sales: decreased -2bps in 2021 and later rose 2bps in 2022.
  • Enanta Pharmaceuticals' Return on Sales stood at 0.01% in 2021, then fell by -13bps to 0.01% in 2022, then plummeted by -51bps to 0.02% in 2023, then grew by 29bps to 0.01% in 2024, then soared by 51bps to 0.01% in 2025.
  • The last three reported values for Return on Sales were 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025) per Business Quant data.